Cereblon-Recruiting PROTACs: Will New Drugs Have to Face Old Challenges?
Open Access
- 2 March 2023
- journal article
- review article
- Published by MDPI AG in Pharmaceutics
- Vol. 15 (3) , 812
Abstract
The classical low-molecular-weight drugs are designed to bind with high affinity to the biological targets endowed with receptor or enzymatic activity, and inhibit their function. However, there are many non-receptor or non-enzymatic disease proteins that seem undruggable using the traditional drug approach. This limitation has been overcome by PROTACs, bifunctional molecules that are able to bind the protein of interest and the E3 ubiquitin ligase complex. This interaction results in the ubiquitination of POI and subsequent proteolysis in the cellular proteasome. Out of hundreds of proteins serving as substrate receptors in E3 ubiquitin ligase complexes, current PROTACs recruit only a few of them, including CRBN, cIAP1, VHL or MDM-2. This review will focus on PROTACs recruiting CRBN E3 ubiquitin ligase and targeting various proteins involved in tumorigenesis, such as transcription factors, kinases, cytokines, enzymes, anti-apoptotic proteins and cellular receptors. The structure of several PROTACs, their chemical and pharmacokinetic properties, target affinity and biological activity in vitro and in vivo, will be discussed. We will also highlight cellular mechanisms that may affect the efficacy of PROTACs and pose a challenge for the future development of PROTACs.Keywords
Funding Information
- Medical University of Lodz (#503/3-045-02/503-31-001-19-00, DEC-2020/04/X/NZ1/00360 Miniatura 4)
- Narodowe Centrum Nauki (#503/3-045-02/503-31-001-19-00, DEC-2020/04/X/NZ1/00360 Miniatura 4)
This publication has 88 references indexed in Scilit:
- High cereblon expression is associated with better survival in patients with newly diagnosed multiple myeloma treated with thalidomide maintenanceBlood, 2013
- Histone deacetylase 6 plays a role as a distinct regulator of diverse cellular processesThe FEBS Journal, 2012
- Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomideLeukemia, 2012
- Damage-specific DNA binding protein 1 (DDB1): a protein with a wide range of functionsThe International Journal of Biochemistry & Cell Biology, 2011
- Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomideBlood, 2011
- Identification of a Primary Target of Thalidomide TeratogenicityScience, 2010
- CRL4s: the CUL4-RING E3 ubiquitin ligasesTrends in Biochemical Sciences, 2009
- Targeted intracellular protein degradation induced by a small molecule: En route to chemical proteomicsBioorganic & Medicinal Chemistry Letters, 2008
- EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinibProceedings of the National Academy of Sciences of the United States of America, 2004
- Cytochrome P450 CYP1B1 protein expression:Biochemical Pharmacology, 2001